Using Biologics to Reduce Long-Term Corticosteroid Use in Pyoderma Gangrenosum: Real-World Evidence From Two Centres.

IF 1.8 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2025-05-27 DOI:10.1111/ajd.14532

R Cascio Ingurgio, A Alfano, L Gargiulo, L Ibba, A Narcisi, F Satgé, M Stark, A Costanzo, D F Murrell

{"title":"Using Biologics to Reduce Long-Term Corticosteroid Use in Pyoderma Gangrenosum: Real-World Evidence From Two Centres.","authors":"R Cascio Ingurgio, A Alfano, L Gargiulo, L Ibba, A Narcisi, F Satgé, M Stark, A Costanzo, D F Murrell","doi":"10.1111/ajd.14532","DOIUrl":null,"url":null,"abstract":"Background: Pyoderma gangrenosum (PG) is a challenging inflammatory skin disorder. While corticosteroids offer a rapid response, their long-term risks necessitate alternative treatments.Objective: To compare the long-term effectiveness of biologic therapies versus systemic corticosteroids in PG management.Methods: A retrospective analysis of 15 PG patients from two centres (Sydney, Australia, and Milan, Italy) was conducted. Patients received either biologic therapies (n = 8) or corticosteroids (n = 7), with ulcer healing outcomes assessed at weeks 16, 28-32 and 54.Results: At week 16, corticosteroids led to faster ulcer reduction and re-epithelialisation. However, biologic-treated patients showed sustained improvement over time, supporting their role in long-term PG management.Conclusion: While corticosteroids provide an initial advantage, biologics demonstrate gradual and sustained efficacy, suggesting a long-term therapeutic role in PG treatment.","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334807/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ajd.14532","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Pyoderma gangrenosum (PG) is a challenging inflammatory skin disorder. While corticosteroids offer a rapid response, their long-term risks necessitate alternative treatments.

Objective: To compare the long-term effectiveness of biologic therapies versus systemic corticosteroids in PG management.

Methods: A retrospective analysis of 15 PG patients from two centres (Sydney, Australia, and Milan, Italy) was conducted. Patients received either biologic therapies (n = 8) or corticosteroids (n = 7), with ulcer healing outcomes assessed at weeks 16, 28-32 and 54.

Results: At week 16, corticosteroids led to faster ulcer reduction and re-epithelialisation. However, biologic-treated patients showed sustained improvement over time, supporting their role in long-term PG management.

Conclusion: While corticosteroids provide an initial advantage, biologics demonstrate gradual and sustained efficacy, suggesting a long-term therapeutic role in PG treatment.

Abstract Image

查看原文本刊更多论文

使用生物制剂减少坏疽性脓皮病长期使用皮质类固醇：来自两个中心的真实世界证据。

背景：坏疽性脓皮病（PG）是一种具有挑战性的炎症性皮肤病。虽然皮质类固醇能提供快速反应，但其长期风险需要替代治疗。目的：比较生物疗法与全身性糖皮质激素治疗PG的远期疗效。方法：回顾性分析来自两个中心（澳大利亚悉尼和意大利米兰）的15例PG患者。患者接受生物治疗（n = 8）或皮质类固醇治疗（n = 7），在第16周、28-32周和54周评估溃疡愈合结果。结果：在第16周，皮质类固醇导致溃疡更快的减少和再上皮化。然而，随着时间的推移，生物制剂治疗的患者表现出持续的改善，这支持了它们在长期PG治疗中的作用。结论：虽然皮质类固醇具有最初的优势，但生物制剂具有逐渐和持续的疗效，表明在PG治疗中具有长期的治疗作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.